Could a cancer drug shield young transplant patients from a deadly complication?
NCT ID NCT03842696
First seen Jan 29, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vorinostat, then checking if it lowers the rate of moderate-to-severe GVHD within 100 days after transplant. The trial enrolled 43 participants across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vorinostat
What this could lead to
If it works, this could point toward a safer way to prevent graft-versus-host disease in young transplant patients, reducing a major complication.
What could go wrong
This is an early phase 1/2 trial with only 43 participants, so results may not apply broadly. Vorinostat may not reduce GVHD or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.